01—Abstract
Summary
Summary of the 8-K filed January 22, 2024. Cited figures are marked; the original filing is the authoritative source.
On January 21, 2024, ADM disclosed that its Board placed Chief Financial Officer and SVP Vikram Luthar on administrative leave, pending an Audit Committee-overseen investigation by outside counsel into accounting practices and procedures in the Nutrition reporting segment, including certain intersegment transactions.
The probe began after ADM received a voluntary document request from the SEC, and the company says it is cooperating. Ismael Roig, a 20-year ADM veteran who most recently led EMEA and Animal Nutrition, was appointed Interim CFO. The company also delayed its Q4 and full-year 2023 earnings release, conference call, and Form 10-K filing from their historical schedule, with an update on timing to follow.
On the financial side, ADM now expects full-year 2023 adjusted EPS above $6.90a, subject to completion of year-end close and internal controls. Operating profit for the Ag Services & Oilseeds (AS&O) and Carbohydrate Solutions segments is expected in line with October 24, 2023 guidance, but ADM withdrew all forward-looking outlook for the Nutrition segment. For investors, the central uncertainty is the scope and outcome of the investigation, the potential for restated or changed Nutrition results, the timing of the delayed 10-K, and the possibility of further SEC action.
The company explicitly declined to forecast GAAP EPS, citing the difficulty of predicting impairments, charges, and legal or tax outcomes that could be material. Investors should treat the $6.90b figure as conditional and monitor the next filings and disclosures closely.
02—Key points
Key Highlights
- CFO Vikram Luthar placed on administrative leave effective immediately (announced Jan 19 decision) pending an Audit Committee investigation into Nutrition segment accounting and intersegment transactions.
- Investigation was triggered by a voluntary SEC document request; ADM states it is cooperating fully with the SEC.
- Ismael Roig (age 56, ADM since 2004, most recently President of EMEA and Animal Nutrition) appointed Interim CFO.
- Preliminary FY2023 adjusted EPS guidance of above $6.90, subject to completion of annual close processes and internal controls.
- Q4/FY2023 earnings release, conference call, and Form 10-K filing delayed from the historical schedule; new timing to be announced.
- All forward-looking outlook for the Nutrition reporting segment withdrawn; AS&O and Carbohydrate Solutions operating profit expected in line with October 2023 indications.
- Company declines to provide GAAP EPS forecast, warning that impairments, restructuring charges, and legal or tax outcomes could be material.
03—Questions
Frequently Asked Questions
Why was the CFO placed on administrative leave?
The Board placed Vikram Luthar on administrative leave pending an ongoing investigation by outside counsel and the Audit Committee into accounting practices and procedures in the Nutrition reporting segment, including certain intersegment transactions. The probe followed a voluntary SEC document request. The leave is not a finding of wrongdoing, and the investigation's outcome is still unknown.
Who is Ismael Roig and what is his background?
Roig, 56, joined ADM in 2004 and most recently served as President of EMEA and President of Animal Nutrition (appointed late 2022). Earlier roles included President of Carbohydrates Solutions International, founding Global BioSolutions, and SVP/Chief Strategy and Sustainability Officer for Asia Pacific. Before ADM he spent 11 years at General Motors in treasury, finance, and controller roles. He holds an MBA from Darden and a CFA credential.
Will ADM still meet its 2023 earnings expectations?
ADM now expects FY2023 adjusted EPS above $6.90, but this is conditional on completing year-end close processes and related internal controls. Operating profit for AS&O and Carbohydrate Solutions is expected to be in line with October 2023 indications. Nutrition guidance has been withdrawn entirely, so the Nutrition contribution to results is uncertain.
When will ADM file its 2023 annual report and report Q4 results?
ADM has delayed its Q4 and full-year 2023 earnings release, conference call, and Form 10-K filing from their historical schedule. The company said it will provide an update on timing as soon as practicable, so no new date had been set as of this filing.
What are the main risks for investors from this announcement?
Key risks include the investigation's scope and results, possible restatements or changes to Nutrition segment results, failure to file 2023 reports on time, possible further SEC action, and market and stakeholder reaction. ADM also warned that impairments, restructuring and other charges, and legal or tax outcomes could materially affect GAAP earnings, and it did not provide a GAAP EPS forecast.
04—Continue